Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study-Reference-Cited by-同舟云学术

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Published:2021-10-21 Issue:12 Volume:51 Page:1229-1241
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Rimini Margherita¹,Shimose Shigeo²^ORCID,Lonardi Sara³⁴,Tada Toshifumi⁵^ORCID,Masi Gianluca⁶,Iwamoto Hideki²,Lai Eleonora⁷,Burgio Valentina⁸,Hiraoka Atsushi⁹^ORCID,Ishikawa Toru¹⁰,Soldà Caterina⁴,Shirono Tomotake²,Vivaldi Caterina⁶,Takaguchi Koichi¹¹,Shimada Noritomo¹²,Astara Giorgio⁷,Koga Hironori²,Nouso Kazuhiro¹³,Joko Kouji¹⁴^ORCID,Torimura Takuji²,Hiasa Yoichi¹⁵^ORCID,Salani Francesca⁶,Scartozzi Mario⁷,Cascinu Stefano⁸,Casadei‐Gardini Andrea⁸

Affiliation:

1. Division of Oncology, Department of Oncology and Hematology University of Modena and Reggio Emilia Modena Italy

2. Division of Gastroenterology, Department of Medicine Kurume University School of Medicine Kurume Japan

3. Early Phase Clinical Trial Unit, Department of Oncology Veneto Institute of Oncology IOV‐IRCCS Padua Italy

4. Medical Oncology Unit 1, Department of Oncology Veneto Institute of Oncology IOV—IRCCS Padua Italy

5. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan

6. Unit of Medical Oncology Pisa University Hospital Pisa Italy

7. Medical Oncology Unit University Hospital and University of Cagliari Cagliari Italy

8. Department of Medical Oncology IRCCS San Raffaele Hospital Milan Italy

9. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

10. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

11. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

12. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

13. Department of Gastroenterology Okayama City Hospital Okayama Japan

14. Hepato‐biliary Center Matsuyama Red Cross Hospital Matsuyama Japan

15. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Matsuyama Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13718

Reference35 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

3. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis

4. Sorafenib in Advanced Hepatocellular Carcinoma

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells;PLOS ONE;2024-03-25

2. Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab;Liver International;2024-03-22

3. A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma;Computers in Biology and Medicine;2024-02

4. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma;Targeted Oncology;2024-01

5. Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis;JGH Open;2023-12